Sign In
Buy HEPA
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
08:30am, Wednesday, 05'th Jan 2022
- Oral Presentation Chosen as a “Distinguished” Abstract - - Oral Presentation Chosen as a “Distinguished” Abstract -
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
01:45pm, Tuesday, 16'th Nov 2021 GlobeNewswire Inc.
EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeuti
HEPA Stock: Why It Increased Today
01:19pm, Wednesday, 29'th Sep 2021
The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased by over 7% during intraday trading today. This is why it happened.
All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431
09:00am, Wednesday, 29'th Sep 2021
EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
04:19pm, Tuesday, 21'st Sep 2021
On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial."
Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial
09:41am, Monday, 13'th Sep 2021
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial. Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
HEPA Stock: Why It Increased Today
06:27am, Monday, 13'th Sep 2021
The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased over 15% pre-market. This is why it happened.
Why Are Hepion Pharma Shares Moving Higher Premarket Monday?
05:56am, Monday, 13'th Sep 2021
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today, Hepion will share additional d
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in NASH
04:05pm, Friday, 10'th Sep 2021
EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
02:17pm, Wednesday, 08'th Sep 2021
These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information |
Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
12:33pm, Wednesday, 08'th Sep 2021
Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical res
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
04:40pm, Friday, 23'rd Jul 2021
EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment
Hepion Pharma's NASH Candidate Aces Mid-Stage Study
09:08am, Tuesday, 13'th Jul 2021
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive topline results from its Phase 2a AMBITION NASH clinical trial evaluating CRV431, a potent inhibitor of cyclophilins. In the trial,
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
04:30pm, Friday, 25'th Jun 2021
EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
07:45am, Wednesday, 09'th Jun 2021
EDISON, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-drive
